dc.contributor.author | Güzel, Eda Çelik | |
dc.contributor.author | Yıldız, Tülin | |
dc.contributor.author | Büyükkıyıcı, O. | |
dc.contributor.author | Dombaz, O.E. | |
dc.date.accessioned | 2023-04-20T08:05:56Z | |
dc.date.available | 2023-04-20T08:05:56Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0030-9982 | |
dc.identifier.uri | https://doi.org/10.47391/JPMA.4844 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/11121 | |
dc.description.abstract | Objective: To assess adverse effects post-vaccination in healthcare professionals in the first vaccinated group against coronavirus disease-2019. Method: The prospective study was conducted at the vaccination unit of a university hospital in Tekirdag, Turkey, from January to February 2021, and comprised healthcare professionals who came for receiving the second dose of the coronavirus disease-2019 inactivated severe acute respiratory syndrome coronavirus 2 vaccine 28 days after the first dose. Data was analysed using SPSS 18. Results: Of the 1088 subjects, 714(65.6%) were female with mean age 29.85±9.2 years and 374(34.4%) were male with mean age 29.57±9.85 years. Overall, local pain in the vaccinated area 495(45.5%), fatigue 266(24.4%), headache 261(23.9%) and muscle pain 197(18.1%) were very common adverse effects. Conclusion: Inactivated severe acute respiratory syndrome coronavirus 2 vaccine was found to be safe. © 2022 Pakistan Medical Association. All rights reserved. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Pakistan Medical Association | en_US |
dc.identifier.doi | 10.47391/JPMA.4844 | |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | CoronaVac | en_US |
dc.subject | Healthcare professionals | en_US |
dc.subject | Post-vaccination adverse effects | en_US |
dc.subject | coronavac | en_US |
dc.subject | adult | en_US |
dc.subject | adverse drug reaction | en_US |
dc.subject | ageusia | en_US |
dc.subject | anosmia | en_US |
dc.subject | arthralgia | en_US |
dc.subject | Article | en_US |
dc.subject | coronavirus disease 2019 | en_US |
dc.subject | coughing | en_US |
dc.subject | descriptive research | en_US |
dc.subject | diarrhea | en_US |
dc.subject | drug safety | en_US |
dc.subject | epiphora | en_US |
dc.subject | fatigue | en_US |
dc.subject | female | en_US |
dc.subject | fever | en_US |
dc.subject | headache | en_US |
dc.subject | health care personnel | en_US |
dc.subject | human | en_US |
dc.subject | injection site pain | en_US |
dc.subject | loss of appetite | en_US |
dc.subject | lymphadenopathy | en_US |
dc.subject | male | en_US |
dc.subject | myalgia | en_US |
dc.subject | nausea and vomiting | en_US |
dc.subject | nose obstruction | en_US |
dc.subject | polymerase chain reaction | en_US |
dc.subject | prospective study | en_US |
dc.subject | rash | en_US |
dc.subject | rhinorrhea | en_US |
dc.subject | Severe acute respiratory syndrome coronavirus 2 | en_US |
dc.subject | skin redness | en_US |
dc.subject | skin tingling | en_US |
dc.subject | sore throat | en_US |
dc.subject | swelling | en_US |
dc.subject | Turkey (republic) | en_US |
dc.subject | vaccination | en_US |
dc.title | Safety and Adverse Effects of Inactive SARS-Cov-2 Vaccine (CoronaVac) in Health Care Professionals | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of the Pakistan Medical Association | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Aile Hekimliği Ana Bilim Dalı | en_US |
dc.identifier.volume | 72 | en_US |
dc.identifier.issue | 9 | en_US |
dc.identifier.startpage | 1792 | en_US |
dc.identifier.endpage | 1796 | en_US |
dc.institutionauthor | Güzel, Eda Çelik | |
dc.institutionauthor | Büyükkıyıcı, O | |
dc.institutionauthor | Dombaz, O.E. | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 42661653300 | |
dc.authorscopusid | 55979875100 | |
dc.authorscopusid | 57907596700 | |
dc.authorscopusid | 57907393700 | |
dc.identifier.scopus | 2-s2.0-85138810624 | en_US |